Last edition
News about "MSN Laboratories "
MSN Laboratories Launches SEMABEST, India's First Semaglutide After Patent Expiry
MSN Laboratories launches SEMABEST, India’s first semaglutide post patent expiry, priced 50 percent lower than the innovator drug and available as a pre-filled pen for improved patient access.
MSN Laboratories | 15/04/2026 | By News Bureau
MSN Laboratories Launches Affordable JAK Inhibitors to Boost Access for Indian Patients
The launch of JAK inhibitors enhances the accessibility and affordability of advanced treatments for patients suffering from various autoimmune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease and Atopic Dermatitis. Both molecules are also approved by the US FDA.
MSN Laboratories | 14/10/2025 | By Dineshwori | 450
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy